USE OF COMPOUND KYA1797K IN PREPARATION OF ANTI-RNA VIRUS DRUG

The use of a compound KYA1797K in the preparation of an anti-RNA virus drug. In particular, the compound has an anti-RNA virus effect, which is mainly due to the fact that the small molecule KYA1797K can inhibit the infection and replication of VSV and SARS-CoV2. The small molecule can be used as a potential clinical trial drug for treating VSV and SARS-CoV2 infection-related diseases, is expected to become a new therapeutic means to prolong the survival period of a patient and improve the survival quality of a patient, and also has an important prompting effect on treating RNA virus-related tumors..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 30. März Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

ZENG MUSHENG [VerfasserIn]
WEN SHIJUN [VerfasserIn]
DAI DANLING [VerfasserIn]
ZHANG HUA [VerfasserIn]
ZHONG QIAN [VerfasserIn]
FENG GUOKAI [VerfasserIn]
ZHAO JINCUN [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-03-30, Last update posted on www.tib.eu: 2023-07-05, Last updated: 2023-07-14

Patentnummer:

WO2023044966

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA017119693